Page 6 - Spirovant Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(1) Urovant Sciences (Nasdaq: UROV) announced today that the independent Data and Safety Monitoring Board (DSMB) has recommended the continuation of the phase 2a study of URO-902, a novel gene therapy product, in patients with overactive bladder (OAB) and urge urinary incontinence (UUI). URO-902 has the potential to be the first gene therapy for patients with OAB. Following the recommendation of the DSMB, Urovant is proceeding with opening cohort 2 of the study with a dose of 48 mg or placebo. About the Phase 2a Study This randomized, double blind, placebo-controlled study will evaluate the ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. UPDATE - Sumitovant Biopharma Announces Myovant Sciences and Pfizer Enter Collaboration to ... Sumitovant BiopharmaDecember 28, 2020 GMT Myrtle Potter, CEO Sumitovant Biopharma “By forming a transformative collaboration with Myovant Sciences and Pfizer, we have taken steps to help position ORGOVYX for advanced prostate cancer and relugolix once-daily combination for Women’s Health for success.” Myrtle Potter, CEO Sumitovant Biopharma “By forming a transformative collaboration with Myovant Sc...

Press release content from Business Wire. The AP news staff was not involved in its creation. Urovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB) December 23, 2020 GMT IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dec 23, 2020-- Urovant Sciences (Nasdaq: UROV) announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for once-daily 75 mg GEMTESA® (vibegron), a beta-3 adrenergic receptor (β3) agonist, for the treatment of overactive bladder (OA...

Posted on 16366 Urovant Sciences (Nasdaq: UROV) announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for once-daily 75 mg GEMTESA® (vibegron), a beta-3 adrenergic receptor (β3) agonist, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence (UUI), urgency, and urinary frequency in adults. This approval marks the first new oral branded OAB medication approved by the FDA since 2012, and it is the first product approval for Urovant Sciences. �...

Dec 23, 2020 21:05 UTC Urovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB) IRVINE, Calif. & BASEL, Switzerland--(Business Wire)--Urovant Sciences (Nasdaq: UROV) announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for once-daily 75 mg GEMTESA® (vibegron), a beta-3 adrenergic receptor (β3) agonist, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence (UUI), urgency, and urinary frequency in adults. This approv...